AB
ABOS.O
—
NASDAQ
Biotechnology & Medical Research
Acumen Pharmaceuticals Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-172,3 %
Net margin
—
Debt / equity
0,44
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$2,42
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Acumen Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of diagnostic products for the detection of infectious diseases.
Business. Acumen Pharmaceuticals Inc (ABOS.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a product-sale entity focused on healthcare diagnostics.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Franklin Advisers, Inc.
largest disclosed fund holder
Profitability→
-172,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ABOS.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Acumen Pharmaceuticals Inc (ABOS.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a product-sale entity focused on healthcare diagnostics.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDAcumen Pharmaceuticals Inc has a liquidity position characterized by a current ratio of 4.07, indicating strong short-term liquidity. The company holds $53.99 million in cash and equivalents, which is a significant portion of its total assets of $122.83 million. However, the company reported negative operating cash flow of -$115.54 million and free cash flow of -$121.37 million, reflecting ongoing cash outflows from operations.
The company's profitability metrics are negative, with a return on equity of -1.72 and a return on assets of -0.99, indicating that it is not generating returns for shareholders or asset holders. These figures are below the industry median for return on equity and return on assets, which are typically positive for companies in the biotechnology and medical research sector.
Acumen Pharmaceuticals Inc operates in a single business segment focused on healthcare diagnostics, with no disclosed geographic revenue concentration. The company's revenue is not segmented by geography in the available data, but its operations are primarily based in the United States.
The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating income and net income have been negative, with a net loss of $121.34 million in the latest reporting period. The company's capital expenditures were minimal at -$88,000, suggesting limited investment in physical assets.
The risk assessment for Acumen Pharmaceuticals Inc indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.44, suggesting a relatively conservative capital structure. The company has not disclosed any recent events in filings or transcripts that would indicate significant operational or financial changes.
Key takeaways
- Acumen Pharmaceuticals Inc has strong liquidity with a current ratio of 4.07 but is experiencing negative cash flows from operations.
- The company's profitability metrics are negative, with a return on equity of -1.72 and a return on assets of -0.99.
- The company operates in a single business segment focused on healthcare diagnostics, with no disclosed geographic revenue concentration.
- The company's growth trajectory is uncertain, with no specific revenue growth projections provided and negative operating and net income.
- The risk assessment indicates low liquidity and dilution risk, with a debt-to-equity ratio of 0.44.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$2,27
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$70.4M
Net cashⓘ
$22.8M
Current ratioⓘ
4.1
Debt / equityⓘ
0.4
ROAⓘ
-98.8%
ROEⓘ
-1.7%
Cash conversionⓘ
95.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
Partners4
Halozyme Therapeutics IncHALO.OPartner95%Source ↗
Jcr Pharmaceuticals Co Ltd4552.TPartner95%Source ↗
LONZA GROUP AGLON.NLBPartner95%Source ↗
MERCK & CO., INC.MRK.OPartner95%Source ↗
Supply chain
Vendors → ABOS ↔ Partners → Customers · click any node to drill
4 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution6 analysts
Strong buy4
Buy2
Hold0
Sell0
Strong sell0
12-month price target$7,20 · Median $8,00
Low $4,00High $10,00
Operating income · consensus-106,4M USD
EPS surprise
−40,5 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,00
Mean$7,20
Median$8,00
High$10,00
Spot$2,27
+216.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-172,3 %Bottom quartile
D/E0,44Bottom quartile
Cash Conv0,95Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 527 148 sh6 exercises · 14 grants14 insiders
- Director · Stock Option (right to buy) → Common StockDisposed 13 040 @ $1,07exercise · 2026-06-17
- Director · Stock Option (right to buy) → Common StockDisposed 6 460 @ $1,07exercise · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 53 250 @ $2,29grant · 2026-06-03
- Chief Legal Officer & Corp Sec · Employee Stock Option (right to buy) → Common StockDisposed 2 090 @ $1,85exercise · 2026-03-06
- Chief Legal Officer & Corp Sec · Employee Stock Option (right to buy) → Common StockDisposed 9 406 @ $1,85exercise · 2026-02-27
- Chief Legal Officer & Corp Sec · Employee Stock Option (right to buy) → Common StockDisposed 2 671 @ $1,85exercise · 2026-01-28
- Chief Legal Officer & Corp Sec · Employee Stock Option (right to buy) → Common StockDisposed 15 085 @ $1,85exercise · 2026-01-26
- Director, Chief Executive Officer · Employee Stock Option (right to buy) → Common StockAcquired 450 000 @ $1,86grant · 2026-01-20
- Chief Regulatory Officer · Employee Stock Option (right to buy) → Common StockAcquired 126 900 @ $1,89grant · 2026-01-16
- Chief Operating Officer · Employee Stock Option (right to buy) → Common StockAcquired 126 900 @ $1,89grant · 2026-01-16
- Chief Medical Officer · Employee Stock Option (right to buy) → Common StockAcquired 148 700 @ $1,89grant · 2026-01-16
- CFO & Chief Business Officer · Employee Stock Option (right to buy) → Common StockAcquired 148 700 @ $1,89grant · 2026-01-16
- Chief Legal Officer & Corp Sec · Employee Stock Option (right to buy) → Common StockAcquired 148 700 @ $1,89grant · 2026-01-16
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
Source documents
- Acumen Pharmaceuticals Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-06-300,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 19 sellsnet -$235K14 insiders · last 365d
- Director · Common StockSold 13 040 @ $2,33$30K · 2026-06-17
- Director · Common StockOther 13 040 @ $1,07$14K · 2026-06-17
- Director · Common StockSold 12 800 @ $2,33$30K · 2026-06-16
- Director · Common StockSold 6 460 @ $2,35$15K · 2026-06-15
- Director · Common StockOther 6 460 @ $1,07$7K · 2026-06-15
- Director · Common StockSold 6 400 @ $2,23$14K · 2026-06-09
- Director · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director, 10% owner · Common StockOther 35 500 · 2026-06-03
- Director · Common StockOther 35 500 · 2026-06-03
- Director, 10% owner · Common StockOther 6 060 606 @ $3,30$20,0M · 2026-03-16
- Chief Legal Officer & Corp Sec · Common StockOther 2 090 @ $1,85$4K · 2026-03-06
- Chief Legal Officer & Corp Sec · Common StockSold 2 090 @ $3,26$7K · 2026-03-06
- Chief Legal Officer & Corp Sec · Common StockOther 9 406 @ $1,85$17K · 2026-02-27
- Chief Legal Officer & Corp Sec · Common StockSold 9 406 @ $3,01$28K · 2026-02-27
- Chief Legal Officer & Corp Sec · Common StockSold 2 671 @ $3,00$8K · 2026-01-28
- Chief Legal Officer & Corp Sec · Common StockOther 2 671 @ $1,85$5K · 2026-01-28
- Chief Legal Officer & Corp Sec · Common StockSold 15 085 @ $3,00$45K · 2026-01-26
- Chief Legal Officer & Corp Sec · Common StockOther 15 085 @ $1,85$28K · 2026-01-26
- Chief Legal Officer & Corp Sec · Common StockSold 5 633 @ $1,90$11K · 2026-01-23
- CFO & Chief Business Officer · Common StockSold 1 687 @ $1,86$3K · 2026-01-22
Short positioning
2.8Mshares short+0.9% vs prior
7.51days to cover
80.5%short of daily vol
49fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ABOS.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Operating income (YoY) (2025-12-31 vs 2024-12-31): -8.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -61.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -48.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -8.3%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -23.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -18.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -34.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 11.8%Derived (calculated)
- Return on equity (FY 2025-12-31): -172.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -98.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.07xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.74xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 51.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -17.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -17.0%Derived (calculated)
- Shareholders' equity (annual): USD 70.43MSEC XBRL filing
- Operating cash flow (annual): USD -115.54MSEC XBRL filing
- Current liabilities (annual): USD 30.01MSEC XBRL filing
- Net income (annual): USD -121.33MSEC XBRL filing
- Shares outstanding (annual): 60.58MSEC XBRL filing
- Total operating expenses (annual): USD 123.83MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
- Long-term debt (annual): USD 22.4MSEC XBRL filing
- Total liabilities (annual): USD 52.4MSEC XBRL filing
Showing 24 of 47 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-17 00:00 UTCINSIDER24 insider transactions — 2026-06 · $110k gross 10 derivative
2026-06-17INSIDERPorter Derrell transacted 13.0k sh — Director ~$14k
2026-06-17INSIDERPorter Derrell sold 13.0k sh — Director ~$30k
2026-06-17INSIDERPorter Derrell disposed of 13.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERPorter Derrell sold 12.8k sh — Director ~$30k
2026-06-15INSIDERPorter Derrell transacted 6.5k sh — Director ~$7k
2026-06-15INSIDERPorter Derrell sold 6.5k sh — Director ~$15k
2026-06-15INSIDERPorter Derrell disposed of 6.5k sh Stock Option (right to buy) — Director
2026-06-09INSIDERFountain Nathan B sold 6.4k sh — Director ~$14k
2026-06-03INSIDERGolumbeski George transacted 35.5k sh — Director
2026-06-03INSIDERStoppel Laura transacted 35.5k sh — Director
2026-06-03INSIDERIves Jeffrey L. transacted 35.5k sh — Director
2026-06-03INSIDERPorter Derrell transacted 35.5k sh — Director
2026-06-03INSIDERStalfort John A III transacted 35.5k sh — Director
2026-06-03INSIDERDrapkin Kimberlee C transacted 35.5k sh — Director
2026-06-03INSIDERFountain Nathan B transacted 35.5k sh — Director
2026-06-03INSIDERRA CAPITAL MANAGEMENT, L.P. transacted 35.5k sh — Director, 10% owner
2026-06-03INSIDERRA CAPITAL MANAGEMENT, L.P. acquired 53.2k sh Stock Option (Right to Buy) — Director, 10% owner
2026-06-03INSIDERFountain Nathan B acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERDrapkin Kimberlee C acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERStalfort John A III acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERPorter Derrell acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERIves Jeffrey L. acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERGolumbeski George acquired 53.2k sh Stock Option (right to buy) — Director
2026-06-03INSIDERStoppel Laura acquired 53.2k sh Stock Option (right to buy) — Director
2026-03-16 00:00 UTCINSIDER4 insider transactions — 2026-03 · net buy $20.0M 1 derivative
2026-03-16INSIDERRA CAPITAL MANAGEMENT, L.P. transacted 6.06M sh — Director, 10% owner ~$20.00M
2026-03-06INSIDERMeisner Derek M transacted 2.1k sh — Chief Legal Officer & Corp Sec ~$4k
2026-03-06INSIDERMeisner Derek M sold 2.1k sh — Chief Legal Officer & Corp Sec ~$7k
2026-03-06INSIDERMeisner Derek M disposed of 2.1k sh Employee Stock Option (right to buy) — Chief Legal Officer & Corp Sec
Showing the 40 most recent of 57 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage